Janney Montgomery Scott LLC Sells 1,266 Shares of argenx SE (NASDAQ:ARGX)

Janney Montgomery Scott LLC cut its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 61.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 806 shares of the company's stock after selling 1,266 shares during the quarter. Janney Montgomery Scott LLC's holdings in argenx were worth $496,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ARGX. Cromwell Holdings LLC lifted its holdings in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after buying an additional 66 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of argenx by 47.5% during the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock valued at $94,000 after buying an additional 56 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company's stock valued at $201,000 after buying an additional 298 shares during the last quarter. Keudell Morrison Wealth Management acquired a new stake in shares of argenx during the 3rd quarter valued at about $207,000. Finally, SG Americas Securities LLC lifted its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after buying an additional 21 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Up 0.3 %

NASDAQ:ARGX traded up $2.25 during trading hours on Thursday, reaching $651.34. The company had a trading volume of 186,351 shares, compared to its average volume of 265,409. The firm has a market capitalization of $39.58 billion, a PE ratio of -740.16 and a beta of 0.58. The stock has a 50-day moving average of $639.27 and a two-hundred day moving average of $580.83. argenx SE has a one year low of $349.86 and a one year high of $678.21.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ARGX shares. Wedbush restated an "outperform" rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. Guggenheim boosted their target price on argenx from $585.00 to $665.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Truist Financial restated a "buy" rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. JPMorgan Chase & Co. boosted their target price on argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a report on Monday, November 4th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $675.00 price target (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.